Sweden's InDex raises $20M for PhIII ulcerative colitis drug; GSK hunts for academic partners;

@FierceBiotech: Sanofi grabs a discovery pact with gut expert Ardelyx in $198M deal. Story | Follow @FierceBiotech

@JohnCFierce: Have to wonder about these bullish peak sales forecasts on dulaglutide. Are patients ready to switch based on easier dosing? | Follow @JohnCFierce

@DamianFierce: InterMune trading up 150% premarket. Here's why. | Follow @DamianFierce

@EmilyMFierce: Global tuberculosis R&D takes hit with AstraZeneca site closure. News | Follow @EmilyMFierce

> Sweden's InDex Pharmaceuticals says it has raised $20 million in a new round led by NeoMed. InDex plans to report Phase III data on Kappaproct, which is being developed for the treatment of severe ulcerative colitis. Release

> GlaxoSmithKline ($GSK) is kicking off its second contest for academic drug hunters, calling for research proposals in the 2014 Discovery Fast Track Challenge, through which investigators have the chance to translate their early-stage research into GSK development programs. Release

> AstraZeneca's VP of global communications, Neil McCrae, is off to join the Royal Mail. Story

> Cambridge, MA-based Verastem ($VSTM) says it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. Release

> New York's Dipexium Pharmaceuticals has set terms for a $30 million IPO, planning to use the haul to develop a late-stage antibiotic treatment for diabetic foot ulcers. More

Medical Device News

@FierceMedDev: Boston Scientific is trying to nip at Medtronic's heels, as far as neuromodulation goes. Has it been successful? Report | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical may not be #1 in neuromodulation, but it is pushing hard to get there. Report | Follow @MarkHFierce

@MichaelGFierce: An FDA panel wants to change iontophoresis drug delivery regulation. More (reg. req) | Follow @MichaelGFierce

@EmilyWFierce: Practice Fusion is teaming up with medical device companies to provide "real-time" accounts of patient health. Article | Follow @EmilyWFierce

> Volcano moves the bar a notch higher for 2014 as restructuring continues. Story

> MIT, Apple and others help shape Quanttus' wearable clinical monitoring tech. More

> India moves closer to approving key medical device legislation. News

Pharma News

@FiercePharma: AbbVie, Amgen and Roche most vulnerable to biosim rivals, Moody's says. More | Follow @FiercePharma

@TracyStaton: With new study, Pfizer closes in on $1B-plus sales boost for #Prevnar vaccine. More | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. Article | Follow @EricPFierce

@CarlyHFierce: Vivus beats the street on licensing payments, but investors aren't fooled. Story | Follow @CarlyHFierce

> U.K. drug reviewers slam BMS' melanoma blockbuster but bless J&J's diabetes pill. More

> The Vasella era ends as Novartis says goodbye to his policies--or is it good riddance? News

Pharma Manufacturing News

> The FDA catches another Indian drugmaker falsifying data. News

> Ranbaxy halts production at 2 plants to tackle its regulatory mess. Story

> The FDA has expanded its equivalency testing of generics. Article

> GSK vows to maintain soccer fields in new U.K. plant. Story

> Hamburg says FDA's focus on India reflects its place in the global supply chain. Story

> Pfizer and MIT are looking for more efficient biologics manufacturing. Brief

Biotech Research News

> Gene therapy regenerates damaged tissue in pigs after heart attack. Story

> Reprogrammed skin cells could provide a way to regenerate liver tissue. Article

> Global tuberculosis R&D takes hit with AstraZeneca site closure. News

> HPV-like vaccine guards against skin tumors in mice. Article

> DOD selects Bavarian Nordic to develop vaccine against biological threats. News

> Berg, Parkinson's Institute partner to find biomarkers. Brief

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.